Costs of postoperative morbidity following paediatric cardiac surgery: observational study

Emma Hudson, Katherine Brown, Christina Pagel, Jo Wray, David Barron, Warren Rodrigues, Serban Stoica, Shane M Tibby, Victor Tsang, Deborah Ridout, Stephen Morris

ABSTRACT

Objective Early mortality rates for paediatric cardiac surgery have fallen due to advancements in care. Alternative indicators of care quality are needed. Postoperative morbidities are of particular interest. However, while health impacts have been reported, associated costs are unknown. Our objective was to calculate the costs of postoperative morbidities following paediatric cardiac surgery.

Design Two methods of data collection were integrated into the main study: (1) case-matched cohort study of children with and without predetermined morbidities; (2) incidence rates of morbidity, measured prospectively.

Setting Five specialist paediatric cardiac surgery centres, accounting for half of UK patients.

Patients Cohort study included 666 children (340 with morbidities). Incidence rates were measured in 3090 consecutive procedures.

Methods Risk-adjusted regression modelling to determine marginal effects of morbidities on per-patient costs. Calculation of costs for hospital providers according to incidence rates. Extrapolation using mandatory audit data to report annual financial burden for the health service.

Outcome measures Impact of postoperative morbidities on per-patient costs, hospital costs and UK health service costs.

Results Seven of the 10 morbidity categories resulted in significant costs, with mean (95% CI) additional costs ranging from £7483 (£3–£17 289) to £66 784 (£40 609–£103 539) per patient. On average all morbidities combined increased hospital costs by 22.3%. Total burden to the UK health service exceeded £21 million each year.

Conclusion Postoperative morbidities are associated with a significant financial burden. Our findings could aid clinical teams and hospital providers to account for costs and contextualise quality improvement initiatives.

INTRODUCTION

Each year more than 5000 paediatric cardiac surgery procedures are performed in the UK. Advancements in preoperative, perioperative and postoperative care have transformed outcomes, greatly reducing mortality in the immediate postoperative period. Patients with complex heart defects and pre-existing conditions now routinely survive surgery. Alternative measures of care quality are needed; postoperative morbidities are considered the next important challenge for clinical teams.

METHODS

Study overview

This study was one element of a 5-year research project to select and define important early morbidities linked to paediatric cardiac surgery and measure their incidence and impact for UK children. The objective of the economic analysis was to calculate the costs of postoperative morbidities following paediatric cardiac surgery.

Regression modelling of patient-level data from a prospective, case-matched cohort study of 666 children was used to measure hospital resource use in patients with and without morbidities. The
incidence of morbidities for 3090 consecutive surgical procedures was measured contemporaneously by study centres (incidence data set), facilitating further analysis of costs at the provider level and an extrapolation using national mandatory audit data to estimate the annual financial burden on the UK health service.

**Setting**

Patients were recruited from October 2015 to June 2017 in five UK centres (Birmingham Children’s Hospital, Bristol Children’s Hospital, Evelina London Children’s Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust, The Royal Hospital for Sick Children Glasgow). Patients and the public were involved in the wider study but not directly in the economic analysis.

**Patients**

The study recruited children from birth to 17 years of age, undergoing open and closed cardiac surgery procedures subject to audit by the National Congenital Heart Disease Audit (NCHDA) (online supplementary appendix 1).

Families with children who met the inclusion criteria were approached to take part in the cohort study unless they were not UK residents, or no family member spoke sufficient English to participate.

The following patients were excluded:

- Premature babies undergoing persistent ductus arteriosus ligation.
- Those undergoing cardiothoracic transplant and tracheal surgeries.
- Those undergoing isolated interventional cardiology procedures.

Each centre attempted to match children with and without morbidities by age, ventricle status (defects of one or both cardiac ventricles) and surgical procedure.

**Classification of morbidities**

Predefined morbidities were extracorporeal life support (ECLS), acute neurological event, unplanned reintervention, feeding problems, major adverse event, prolonged pleural effusion, post-surgical infection morbidity, renal support and necrotising enterocolitis. Definitions have been published previously and are summarised in online supplementary appendix 2.

Patients were categorised as follows:

- Children without postoperative morbidity.
- Children who experienced a single morbidity (not ECLS).
- Children who experienced more than one morbidity not including ECLS.
- Children who needed postoperative ECLS whether on its own or in combination with other morbidities.

**Data collection**

The observation period commenced on the day of the qualifying surgical procedure (day 1) and concluded 6 months later (day 183). Hospital costs were a summation of: operating theatre costs for the initial surgery and any additional procedures; high dependency/intensive care unit (ICU) costs; ward costs and all outpatient visit costs during the observation period. For children who died within the observation period (n = 39), data were collected until the date of death.

**Resource use**

Operating theatre time (minutes) and number of ward days were extracted from hospital information systems. ICU data were extracted from the Paediatric Intensive Care Audit Network database. Number of outpatient visits was reported by families at follow-up visits (6, 12 and 26 weeks). Research staff monitored data for accuracy.

**Unit costs**

Unit costs were obtained from published sources and inflated (2016/2017 UK£) where necessary. Healthcare resource groups were assigned for each day of ICU stay: intensive care extracorporeal membrane oxygenation (ECMO)/ECLS (cost per day £5440); intensive care advanced enhanced (£3748); intensive care advanced (£2538); intensive care basic enhanced (£2151); intensive care basic (£1899); high dependency advanced (£1448); high dependency (£1173); and enhanced care (£870). The daily ward cost of the study centre closest to the mean value for all centres was used; £904 for children <2 years and £680 for children ≥2 years. For operating theatres, the cost per minute closest to the mean across centres (£13.39) was used. Each outpatient visit was assigned published national average costs for paediatric outpatient visits (£199).

**Data analysis**

**Handling missing data**

Measures of inpatient resource had 3%–14% of missing data. Outpatient attendance was reliant on self-reporting, 19% of data were missing. Multiple imputation to account for missing data was undertaken using explanatory variables without missing values. Twenty imputed data sets were generated using an iterative Markov chain Monte Carlo procedure based on multivariate normal regression.

**Case mix adjustment**

Confounding variables from the analysis of clinical outcomes which were predefined and validated were tested using a forward selection and backward elimination technique on imputed data. Variables with a significant (p value <0.05) association with costs were: age, weight by age, congenital morbidity, pre-existing severe illness, Down’s syndrome, cardiac diagnosis, procedure type, death within 6 months and study centre.

**Regression analysis**

We used a generalised linear model with gamma family and log link, recommended for skewed cost data. To account for multiple imputation, coefficients and SEs were computed using combination rules. ‘No morbidities’ was the reference category. Coefficients with p values <0.05 were considered significantly different from zero. All analyses were performed in Stata v14.

Per-patient costs are expressed as marginal effects illustrating the mean difference in 6-month hospital costs between the morbidity category and omitted category (no morbidity), conditional on the covariates. To compute marginal effects we: (1) exponentiated the coefficient for each morbidity; (2) multiplied this by the mean of the omitted category; and (3) subtracted the mean of the omitted category from this product.

**Annual financial burden to the UK health service**

The financial burden to the health service is the additional cost resulting from treating morbidities in the UK population each year. We extrapolated our results to the UK population using the following methods:
Original research

I. We calculated the annual incidence rate at each study centre (A–E) for every morbidity category including the no morbidity category (1-11)(eg, [incidence of morbidity category at site A/months of observation site A]×12= A₁, A²… A¹¹). We summed the rate of each individual category across all study centres (eg, A₁+B₁+C₁+D₁+E₁= S₁); the total of which gives the annual number of procedures across all study sites (S₁+S²…+S¹¹=S¹¹).

II. We identified the rates of equivalent procedures nationally as reported in UK mandatory audits over the same period (2014–2017)³ for all National Health Service (NHS) centres in England, Wales and Scotland. In Ireland, all patients are treated at a single centre. To account for Northern Irish patients, 28% of cases from this centre were included.⁲⁹ The resulting total number of procedures for the UK was averaged over the 3 years ([¹¹]).

IV. We divided the UK population procedure rate by the study procedure rate ([¹¹]S)/S¹¹) to calculate an extrapolation factor to convert study-specific results to national estimates.

V. We multiplied this extrapolation factor by the incidence of each category to estimate the numbers for the UK population and multiplied this by the cost of each category to calculate the national annual burden of each morbidity to the UK health service.

Costs of morbidities for UK hospital providers

In order to contextualise results for hospital providers we applied the per-patient costs to each of the 10 morbidities and the no morbidity category to the annual incidence reported by the 12 UK centres and calculated the variation in costs according to activity.

RESULTS

Study population

Six hundred and sixty-six children were recruited to the cohort study, the proportion in each category was: no morbidity n=326 (48.9%), prolonged pleural effusion n=50 (7.5%), feeding problems n=45 (6.7%), acute neurological event n=6 (0.9%), necrotising enterocolitis n=11 (1.6%), post-surgical infection morbidity n=11 (1.6%), unanticipated re-intervention n=24 (3.6%), renal support n=22 (3.3%), major adverse event n=26 (3.9%), multiple morbidities n=118 (17.7%) and ECLS n=27 (4.0%). Characteristics of patients with and without morbidities are shown in table 1 and by morbidity category in online supplementary appendix 3.

Complete data for 6-month hospital costs (operating theatre costs, high dependency/ICU costs, ward costs and outpatient visits over the 6-month postoperative period) were available for 538 (81%).

Regression analysis

For children without morbidities, the mean-adjusted 6-month predicted cost per patient was £24 143. Regression modelling identified significant marginal effects (increase from £24 143) in seven morbidity categories with mean (95% CI) values of: prolonged pleural effusion £7483 (£3–£17 289); renal support £11 241 (£936–£25 781); necrotising enterocolitis £16 592 (£599–£42 924); feeding problems £17 927 (£8057–£30 824); unplanned re-intervention £22 903 (£9598–£41 456); multimorbidities £37 697 (£25 971–£52 167); and ECLS £66 784 (£40 609–£103 539) (table 2).

Annual financial burden to the UK health service

The total calculated cost of 6-month postoperative hospital services for the UK population was £115 864 753 (£103 162 820–£128 566 686). If no child incurred early postoperative morbidity this cost would be £94 785 418 (£81 931 327–£107 639 509), resulting in an annual financial burden to the NHS from early postoperative morbidities of £21 079 335 (£19 331 430–£22 827 240) (table 3).

Costs of morbidities for hospital service providers

In the UK, there are 12 hospitals performing paediatric cardiac surgery with annual procedure rates ranging from 226 to 628, the average rate per centre is 367 procedures, per year. Applying per-patient costs, we calculated the cost of 6-month postoperative care for the average hospital to be £9 655 396, of which £1 756 611 was additional cost from morbidities, representing a 22.3% increase in costs (table 4). For the centre performing the most procedures in the NCHDA, calculated total cost would be £18 533 638 with £3 371 834 due to morbidities; for the centre performing the fewest procedures, total cost is £6 669 748 with a morbidity burden of £1 213 430.

DISCUSSION

Principal findings

Seven early postoperative morbidities following paediatric cardiac surgery were associated with significant increases in per-patient 6-month hospital costs compared with the same costs for children without morbidity. The magnitude of additional resource use for patients who experience morbidities represents a substantial cost burden for hospital providers, with an average increase in costs for UK centres of 22.3%. When extrapolated to the national patient population, the estimated additional financial burden of early postoperative morbidities for the UK health service exceeds £21 million each year.

Given these considerable costs, our data support the argument that addressing morbidities should be the next major focus for improving outcomes for patients as in addition to clinical gains, care quality improvements that reduce morbidities could also be highly cost-effective.

Strengths and limitations of this research

To our knowledge, this is the first study to report the financial impact of clinically important morbidities for this patient population. Our analysis uses rich patient-level measures of resource use collected specifically for the purpose of measuring costs. Measures of hospital resource use had high level of completeness and the sample population is representative of the UK patient population. In terms of conditions, procedures, risk factors and outcomes. The method of cohort assignment which allocated comparable patients to the case and control cohorts is likely to have reduced intersite variability, which is a limitation often seen in observational cohort studies. For children without morbidities, the survival rate at 6 months was 99.3%, and the median length of stay was 8 days, suggesting that the morbidities selected captured the majority of complication-related adverse outcomes for the population. Monitoring of the incidence of each morbidity category in 3090 consecutive procedures across half of all UK centres over several years facilitated a credible calculation of annual financial burden for the NHS.

The main limitation of our work is that we were only able to illustrate costs for the 6-month period following surgery. The consequences of this fixed observation period are, first, that for
children with the most complex recoveries clinical and cost impacts can extend well beyond this time point, and, second, the variation in length of stay within the 6-month period directly impacted the admissible data collection period for other types of resource use. For our sample population, 95% of children without morbidity had been discharged from the hospital before 6 weeks, therefore, costs of readmissions and outpatient appointments were measured for 18 weeks, whereas 30% of children with multiple morbidities and 48% of those who had ECLS remained in hospital beyond 6 weeks and so those same costs were measured over a shorter period. To account for this, we have been careful to stipulate that our results are representative of the actual costs incurred in the 6 months following surgery. Nevertheless, since the patients with morbidities and a greater length of stay would also have been very likely to require more intense follow-up in the out-of-hospital phase, extending beyond our 6-month window, their true overall

| Table 1 | Characteristics of cohort study patients with and without morbidities |
|---|---|---|
| Variable | Category | No morbidity n=326 (%) | Any morbidity n=340 (%) | Total (%) |
| Sex | Female | 137 (42) | 155 (47) | 292 (44) |
| | Male | 189 (58) | 185 (53) | 374 (56) |
| Income category (per year) | Up to £10 000 | 31 (9) | 24 (7) | 55 (8) |
| | £10 000–£20 000 | 67 (21) | 87 (25) | 154 (23) |
| | £20 001–£50 000 | 118 (36) | 113 (34) | 231 (35) |
| | More than £50 000 | 73 (22) | 57 (16) | 130 (20) |
| | Unknown | 37 (12) | 59 (18) | 96 (14) |
| Survived beyond 6 months | Yes | 322 (99) | 305 (90) | 627 (94) |
| | No | 4 | 35 | 39 (6) |
| Hospital centre | A | 79 (24) | 106 (31) | 185 (28) |
| | B | 69 (21) | 66 (19) | 135 (20) |
| | C | 78 (24) | 78 (23) | 156 (23) |
| | D | 68 (21) | 65 (19) | 133 (20) |
| | E | 32 (10) | 25 (4) | 57 (9) |
| Ethnicity | White | 226 (69) | 219 (64) | 445 (67) |
| | Non-white | 92 (28) | 99 (31) | 191 (29) |
| | Missing | 8 (2) | 22 (6) | 30 (5) |
| Weight for age | Normal | 212 (65) | 219 (64) | 431 (65) |
| | Low | 90 (28) | 103 (30) | 193 (29) |
| | Missing | 24 (7) | 18 (5) | 42 (6) |
| Premature* | No | 300 (92) | 306 (90) | 606 (91) |
| | Yes | 30 (9) | 34 (9) | 64 (9) |
| Congenital comorbidity* | No | 281 (86) | 264 (78) | 545 (82) |
| | Yes | 45 | 76 | 121 (18) |
| Pre-existing severity of illness indicators* | No | 277 (85) | 265 (78) | 542 (81) |
| | Yes | 49 | 75 | 124 (19) |
| Preacquired comorbidity* | No | 279 (85) | 290 (85) | 569 (85) |
| | Yes | 47 | 50 | 97 (15) |
| Down’s syndrome* | No | 299 (92) | 311 (91) | 610 (92) |
| | Yes | 27 | 29 | 56 (8) |
| Pre-existing additional cardiac risk factor† | No | 301 (92) | 309 (91) | 610 (92) |
| | Yes | 35 | 31 | 66 (10) |
| Diagnosis category† | A (most complex) | 40 (12) | 48 (14) | 88 (14) |
| | B | 34 (10) | 56 (16) | 90 (14) |
| | C | 62 (19) | 62 (18) | 124 (19) |
| | D | 89 (27) | 107 (31) | 196 (29) |
| | E (least complex) | 101 (31) | 67 (20) | 168 (25) |
| Procedure category‡ | A: Palliative/staged | 65 (19) | 90 (25) | 155 (23) |
| | B: Reparative/corrective | 190 (58) | 169 (50) | 359 (54) |
| | C: Ambiguous | 71 (22) | 81 (24) | 152 (23) |
| Age category | Neonate | 114 (35) | 146 (43) | 260 (39) |
| | Infant | 130 (40) | 120 (35) | 250 (38) |
| | Child | 82 (25) | 74 (22) | 156 (23) |

*Comorbidities are: preacquired comorbidity; congenital comorbidity excluding Down’s syndrome; Down’s syndrome, additional cardiac risk factors (eg, cardiomyopathy); prematurity; severity of illness indicator.

†Cardiac diagnosis category based on the Partial Risk Adjustment in Surgery (PRAiS2) ranking order and further aggregated by an expert panel, group A the most complex and group E the least (online supplementary appendix 4).

‡Specific procedure category based on National Congenital Heart Disease Audit (NCHDA) algorithm, reparative or corrective operation; palliative or staging operation; ungrouped operation (could not be determined).15
Table 2: Marginal effects of morbidity on 6-month hospital costs (imputed data set)

| Morbidity category                  | Coefficient | P value | Marginal effect (95% CI) |
|-------------------------------------|-------------|---------|-------------------------|
| Extracorporeal life support         | 1.326       | <0.001  | £66.784 (£40.609 to £103.539) |
| Multiple morbidity (except ECLS)    | 0.941       | <0.001  | £37.697 (£25.971 to £52.167) |
| Unplanned reoperation               | 0.667       | <0.001  | £22.903 (£9.598 to £41.456) |
| Feeding problems                    | 0.555       | <0.001  | £17.927 (£8.057 to £30.824) |
| Necrotising enterocolitis           | 0.523       | 0.04    | £16.592 (£5.994 to £42.924) |
| Acute neurological event            | 0.458       | 0.21    | £14.042 (−£5.424 to £53.753) |
| Renal support                       | 0.382       | 0.03    | £11.241 (£9.365 to £25.781) |
| Postoperative infection morbidity   | 0.347       | 0.17    | £10.025 (−£32.666 to £31.779) |
| Prolonged pleural effusion          | 0.270       | 0.05    | £7.483 (E3 to £17.289) |
| Major adverse event                 | 0.189       | 0.32    | £5.030 (−£41.119 to £18.359) |

In every case the regression model was a generalised linear model with gamma family and log link. The marginal effects are the change in costs versus the omitted category (no morbidities). Data include values imputed using multiple imputation. Costs are in 2016/2017 UK£. Controls were also included in every model for: age; weight by age; whether or not the patient had a pre-existing congenital morbidity, pre-existing severe illness or Down’s syndrome; underlying diagnosis prompting cardiac surgery; type of cardiac procedure performed; whether or not the patient died within 6 months; and study centre. ECLS, extracorporeal life support.

Table 3: Annual financial burden to the UK health service

| Morbidity type                  | Marginal effect on costs of morbidity (increase from £24.143) | Total per-patient cost (cost of no morbidity-marginal effect) | Annual morbidity incidence-study centres* | Annual morbidity incidence—study centres extrapolated to UK population | Annual morbidity incidence+marginal cost (cost of no morbidity+marginal effect) | Annual cost to health service morbidity | Annual cost to health service morbidity extrapolated to UK population | Annual national total cost |
|---------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------------------------------------|----------------------------------------|----------------------------------------------------------------------------|------------------------------|
| No morbidity                    |                                                              |                                                               |                                          |                                                                       |                                                                             |                                        |                                                                            |                              |
| Acute neurological event        | £0                                                           | £24.143                                                       | 1415.1                                   | 3066                                                                  | −                                                                           | £74.022 438                                                      |                                                                             |                              |
| Unplanned reoperation           | £22.903                                                      | £47.046                                                      | 34.7                                     | 75                                                                    | £1 717 725                                                              | £3 528 450                                                    |                                                                             |                              |
| Feeding problems                | £17.927                                                      | £42.070                                                      | 52.7                                     | 124                                                                   | £2 222 948                                                              | £5 216 680                                                    |                                                                             |                              |
| Renal support                   | £11.241                                                      | £35.384                                                      | 23.3                                     | 50                                                                    | £562 050                                                               | £1 769 200                                                    |                                                                             |                              |
| Major adverse event             | £0                                                           | £24.143                                                      | 20.4                                     | 44                                                                    | £0                                                                       | £1 062 292                                                    |                                                                             |                              |
| Extracorporeal life support     | £66.784                                                      | £90.927                                                      | 37.5                                     | 81                                                                    | £5 409 504                                                             | £7 365 087                                                    |                                                                             |                              |
| Necrotising enterocolitis       | £16.592                                                      | £40.735                                                      | 19.1                                     | 41                                                                    | £680 272                                                               | £1 670 135                                                    |                                                                             |                              |
| Postoperative infection morbidity| £0                                                           | £24.143                                                      | 16.0                                     | 35                                                                    | £0                                                                       | £845 005                                                    |                                                                             |                              |
| Prolonged pleural effusion      | £7.483                                                       | £31.626                                                      | 65.4                                     | 142                                                                   | £1 062 586                                                             | £4 490 892                                                    |                                                                             |                              |
| Multiple morbidity              | £37.697                                                      | £61.840                                                      | 115.4                                    | 250                                                                   | £9 424 250                                                             | £15 460 000                                                   |                                                                             |                              |
| Total                           |                                                              |                                                               | 1812.4                                   | 3927                                                                  | £21 079 335                                                             | £115 864 753                                                   |                                                                             |                              |

*Calculated from observed incidence rates of 3100 consecutive surgical procedures across all study centres.

Table 4: Costs of morbidities to hospital providers

| Morbidity type                  | Annual incidence of morbidity averaged across 12 NCHDA centres | Average annual marginal cost per provider | Average annual total cost per provider |
|---------------------------------|---------------------------------------------------------------|------------------------------------------|---------------------------------------|
| No morbidity                    | 255.5                                                        | −                                        | £6 168 537                             |
| Acute neurological event        | 1.5                                                          | 0                                        | £36 215                               |
| Unplanned reoperation           | 6.3                                                          | £143.14                                  | £294 038                              |
| Feeding problems                | 10.3                                                         | £185 246                                 | £434 723                              |
| Renal support                   | 4.2                                                          | £46 838                                   | £147 433                              |
| Major adverse event             | 3.7                                                          | 0                                        | £88 524                               |
| Extracorporeal life support     | 6.8                                                          | £450 792                                 | £613 757                              |
| Necrotising enterocolitis       | 3.4                                                          | £56 689                                   | £139 178                              |
| Postoperative infection morbidity| 2.9                                                          | 0                                        | £70 417                               |
| Prolonged pleural effusion      | 11.8                                                         | £88 549                                   | £374 241                              |
| Multiple morbidity              | 20.8                                                         | £785 354                                 | £1 288 333                            |
| Total                           | 327.2                                                        | £1 756 611                                | £9 655 396                            |

NCHDA, National Congenital Heart Disease Audit.

Table 4: Total incidence of morbidity NCHDA reports 2014–2017

| Morbidity type | Total NCHDA reports | Annual incidence morbidity incidence—study centres | Extrapolation factor | Annual total morbidity cost for UK patient population | Annual national total cost with no morbidities | Annual national total cost with morbidities | % increase in cost |
|----------------|---------------------|----------------------------------------------------|----------------------|------------------------------------------------------|-----------------------------------------------|---------------------------------------------|-------------------|
| G              | H (G3)              | I (H4)                                             | J (H1)               | K (J1)                                               | L (K3)                                       | M (K1)                                      | N (JKM+100)       |
| 11 782         | 3927                | 1812.4                                             | 2.167                | £21 079 335                                          | £115 864 753                                 | £94 785 418                                  | 22.3%             |
Unanswered questions and future research
Paediatric cardiac surgery is a highly invasive, traumatic life event for children and their families and there is a need to advance the reporting of costs beyond morbidity and relate them to patients’ postoperative functional status and quality of life.

Finally, the methodology we have used, including the use of costing and outcome data from a number of sources populated as a result of existing reporting, costing and benchmarking initiatives, which are not in principle specific to paediatric cardiac surgery, provides a template that could be adapted more broadly within the NHS to elicit similar insights into other areas where the cost of hospitalisation is analogous to outcomes of interest.

CONCLUSION
Costs associated with postoperative morbidity following paediatric cardiac surgery are substantial. Our research identifies the financial impact of early postoperative morbidities on hospital providers of paediatric surgery and the UK NHS. As mortality rates improve and increasingly complex patients survive their surgery, the cost of postoperative care is likely to rise. Data from analyses of hospital costs and inpatient mortality for paediatric cardiac surgery, the cost of hospitalisation is analogous to outcomes of interest.

REFERENCES
1. NHS England. Paediatric congenital heart disease specification. Available: www.england.nhs.uk
2. Brown KL, Crowe S, Franklin R, et al. Trends in 30-day mortality rate and case mix for paediatric cardiac surgery in the UK between 2000 and 2010. Open Heart 2015;2:e000157
3. National congenital heart disease audit 2014-2017 summary report. Available: https://www.nicor.org.uk/wp-content/uploads/2018/11/National-Congenital-Heart-Disease-Audit-Summary-Report-2014-17.pdf
4. Bach EA, Cooper D, Thiagarajan R, et al. Cardiac complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal database Committee for pediatric and congenital heart disease. Cardiol Young 2008;18(Suppl 2):196–201
5. Bird GL, Jeffries HE, Licht DL, et al. Neurological complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal database Committee for pediatric and congenital heart disease. Cardiol Young 2008;18(Suppl 2):234–9
6. Deal BJ, Mavroudis C, Jacobs JP, et al. Arrhythmia complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal database Committee for pediatric and congenital heart disease. Cardiol Young 2008;18(Suppl 2):202–5
7. Dickerson H, Cooper DS, Checchia PA, et al. Endocardial complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal database Committee for pediatric and congenital heart disease. Cardiol Young 2008;18(Suppl 2):256–64
8. Ghanayem NS, Deodari J, Liebow JA, et al. Gastrointestinal complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal database Committee for pediatric and congenital heart disease. Cardiol Young 2008;18(Suppl 2):240–4
9. Cooper DS, Jacobs JF, Chai PJ, et al. Pulmonary complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal database Committee for pediatric and congenital heart disease. Cardiol Young 2008;18(Suppl 2):215–21
10. Jacobs ML, O’Brien SM, Jacobs JP, et al. An empirically based tool for analyzing morbidity associated with operations for congenital heart disease. J Thorac Cardiovasc Surg 2013;145:1046–57
11. Brown KL, Ridout DA, Goldman AP, et al. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med 2003;31:28–33
12. Romley JA, Chan AV, Goldman DP, et al. Hospital costs and inpatient mortality among children undergoing surgery for congenital heart disease. Health Serv Res 2014;49:588–608
13. Pasquali SK, Jacobs ML, He X, et al. Variation in congenital heart surgery costs across hospitals. Pediatrics 2014;133:e553–60
14. Pasquali SK, Gales MG, Jacobs JP, et al. Centre variation in cost and outcomes for congenital heart surgery. Cardiol Young 2012;22:796–9
15. Crowe S, Brown KL, Pagel C, et al. Development of a diagnosis- and procedure-based risk model for 30-day after pediatric cardiac surgery. J Thorac Cardiovasc Surg 2013;145:1270–8
16. NHS. Safe and Sustainable: Children’s Congenital Cardiac Services, 2011. Available: http://www.çhfed.org.uk/wp-content/uploads/2012/06/Safe_and_Sustainable_-_Review_of_Children’s_Congenital_Cardiac_Services_in_England_Pre-Consultation_Business_Case.pdf
17. National Institute for Health Research. Selection, definition and evaluation of important early morbidities associated with paediatric cardiac surgery. Available: https://www.journalslibrary.nihr.ac.uk/programmes/hsdri/122000506/6/
18. Brown KL, Pagel C, Brimmell R, et al. Definition of important early morbidities related to paediatric cardiac surgery. Cardiol Young 2017;27:747–56
19. NHS Improvement. Reference costs. Available: https://improvement.nhs.uk/resources/reference-costs/ [Accessed 19 Jul 2019]
20. Curtis L, Burns A. Unit costs of health and social care 2016, personal social services research unit, University of Kent, Canterbury unit costs of health and social care 2016, 2016. Available: https://www.psru.ac.uk/project-pages/unit-costs/unit-costs-2016/ [Accessed 19 Jul 2019]
21. NHS Employers. Unit costs of health and social care, 2017. Available: http://www.nhsemployers.org/your-workforce/pay-and-reward/pay/job-evaluation/national-job-profiles
Original research

22. Rubin DB. *Multiple imputation for nonresponse in surveys*. John Wiley & Sons, 1987.

23. Brown KL, Pagel C, Ridout D, et al. What are the important morbidities associated with paediatric cardiac surgery? A mixed methods study. *BMJ Open* 2019;9:e028533.

24. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. *J Health Serv Res Policy* 2004;9:197–204.

25. StataCorp. *Stata statistical software: release 14*. College Station, TX: StataCorp LP, 2015.

26. r - How to interpret parameters in GLM with family=Gamma - Cross Validated. Available: https://stats.stackexchange.com/questions/96972/how-to-interpret-parameters-in-glm-with-family-gamma [Accessed 19 Jul 2019].

27. Population estimates for the UK, England and Wales, Scotland and Northern Ireland - Office for National Statistics. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyeastimates/mid2018 [Accessed 19 Jul 2019].

28. Behrendt K, Groene O. Mechanisms and effects of public reporting of surgeon outcomes: a systematic review of the literature. *Health Policy* 2016;120:1151–61.

29. Ellis J. All inclusive benchmarking. *J Nurs Manag* 2006;14:377–83.

30. Craig R, Moga C, Guo B, et al. The impacts of public reporting and external benchmarking in cardiac care: a rapid update of the literature. Edmonton, AB: Institute of Health Economics, 2017.